Peregrine Capital Management LLC Acquires Shares of 831,515 Iovance Biotherapeutics Inc (IOVA)

Peregrine Capital Management LLC acquired a new stake in Iovance Biotherapeutics Inc (NASDAQ:IOVA) in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 831,515 shares of the biotechnology company’s stock, valued at approximately $7,908,000. Peregrine Capital Management LLC owned approximately 0.67% of Iovance Biotherapeutics at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently modified their holdings of IOVA. Advisor Group Inc. grew its stake in shares of Iovance Biotherapeutics by 58.6% in the fourth quarter. Advisor Group Inc. now owns 8,118 shares of the biotechnology company’s stock valued at $72,000 after buying an additional 3,000 shares in the last quarter. Kalos Management Inc. acquired a new stake in shares of Iovance Biotherapeutics in the fourth quarter valued at $93,000. Great West Life Assurance Co. Can grew its stake in shares of Iovance Biotherapeutics by 67.4% in the fourth quarter. Great West Life Assurance Co. Can now owns 14,538 shares of the biotechnology company’s stock valued at $124,000 after buying an additional 5,853 shares in the last quarter. Amalgamated Bank acquired a new stake in shares of Iovance Biotherapeutics in the fourth quarter valued at $130,000. Finally, Mitsubishi UFJ Kokusai Asset Management Co. Ltd. grew its stake in shares of Iovance Biotherapeutics by 66.9% in the fourth quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 15,374 shares of the biotechnology company’s stock valued at $137,000 after buying an additional 6,162 shares in the last quarter. 95.92% of the stock is owned by institutional investors and hedge funds.

A number of equities research analysts have recently weighed in on the company. Chardan Capital reaffirmed a “buy” rating on shares of Iovance Biotherapeutics in a research note on Wednesday, March 13th. HC Wainwright reaffirmed a “buy” rating and issued a $26.00 price objective on shares of Iovance Biotherapeutics in a research note on Monday, April 1st. BidaskClub raised Iovance Biotherapeutics from a “sell” rating to a “hold” rating in a research note on Thursday, April 4th. Zacks Investment Research cut Iovance Biotherapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, January 15th. Finally, ValuEngine cut Iovance Biotherapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, January 29th. Two investment analysts have rated the stock with a hold rating and eight have given a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus target price of $22.86.



IOVA opened at $11.63 on Monday. Iovance Biotherapeutics Inc has a 12 month low of $7.26 and a 12 month high of $18.25. The firm has a market cap of $1.42 billion, a P/E ratio of -9.16 and a beta of 1.91.

TRADEMARK VIOLATION NOTICE: This story was first published by Dakota Financial News and is the property of of Dakota Financial News. If you are accessing this story on another publication, it was stolen and reposted in violation of international copyright & trademark laws. The correct version of this story can be viewed at https://dakotafinancialnews.com/2019/04/15/peregrine-capital-management-llc-acquires-shares-of-831515-iovance-biotherapeutics-inc-iova.html.

Iovance Biotherapeutics Profile

Iovance Biotherapeutics, Inc, a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. The company's lead product candidate is LN-144, an adoptive cell therapy that is in Phase II clinical trial using tumor-infiltrating lymphocytes (TIL), which are T cells derived from patients' tumors for the treatment of metastatic melanoma.

See Also: How do buyers and sellers choose a strike price?

Institutional Ownership by Quarter for Iovance Biotherapeutics (NASDAQ:IOVA)

Receive News & Ratings for Iovance Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iovance Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.